HUTCHINSON ISLAND, Fla., April 28 /PRNewswire/ -- BSP, developing superior electrocardiograph (ECG) technology with breakthrough diagnostic value for detecting and monitoring ischemic heart diseases (IHD), will be presenting study results conducted with its HyperQ(TM) system, at the International Society for Computerized Electrocardiology (ISCE) 2004 in Florida.
The study, titled "High Frequency Mid-QRS Analysis (HyperQ(TM)) - an Effective Tool for the Monitoring and Diagnosis of Myocardial Ischemia", validates the high diagnostic efficacy of the HyperQ(TM) score for detecting and monitoring ischemic heart disease, far surpassing that of the standard stress ECG, using SPECT nuclear mapping as the gold standard.
One of the more important results that will be presented at the conference relates to a specific sub-population of patients, where expert cardiologists disagreed on the interpretation of conventional ECG readings. For this group, the HyperQ(TM) system demonstrated remarkable results, correctly identifying all non-ischemic subjects (100% specificity) and all ischemic patients (100% sensitivity). The study findings will also appear in a publication at the JEC - Journal of Electrocardiology, following the conference presentation.
A list of previous scientific references underscoring the technology implemented in BSP's system could be found at: http://www.bsp.co.il/publications.shtm.
BSP was founded in 2000 by Dr. Amir Beker, CEO, a graduate of the prestigious 'Talpiot' program of the Israeli Air Force, and a PhD in Medical Physics.
For more information, please visit us at http://www.bsp.co.il/ or contact email@example.com.
Yuval Raviv, Vice President, +972-3-6474840, firstname.lastname@example.org
Dr. Amir Beker, CEO, email@example.com
BSP Biological Signal Processing Ltd
CONTACT: Yuval Raviv, Vice President, +972-3-6474840, firstname.lastname@example.org,or Dr. Amir Beker, CEO, email@example.com, both of BSP Biological SignalProcessing Ltd